Chronic Lymphocytic Leukemia (CLL) | Norton Healthcare

Indication: Chronic Lymphocytic Leukemia (CLL)

ULTRA-V: Phase 2 Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Previously treated patients

Sub-indication: CLL

Line of Therapy: 2nd

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: TG Therapeutics, Inc

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.